Last reviewed 2026-04-19 · How we verify

Non-small cell lung cancer

Approved treatments

• PF-07220060 + PF-07104091 combination dose escalation · Pfizer
• PF-06939999 in combination with docetaxel · Pfizer
• Alunbrig · Takeda
  Alunbrig works by blocking the activity of the ALK tyrosine kinase receptor, which is involved in the growth and spread of cancer cells.
• ICOTINIB · Zhejiang Beta Pharma Inc.
• Gemcitabin · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Iressa · David Adelstein
• Camtobell · Chong Kun Dang
• Zykadia · Novartis
  Zykadia blocks the activity of the ALK protein, which is involved in the growth and spread of cancer cells.
• Gemzar · Accord Hlthcare
  Gemcitabine kills cells during DNA synthesis and blocks G1/S-phase progression.
• Ofev · Boehringer Ingelheim
  Ofev works by blocking enzymes that promote fibrosis and tumor growth.
• Portrazza · Eli Lilly Co
  Portrazza works by blocking the epidermal growth factor receptor (EGFR) protein, which is involved in cancer cell growth and proliferation.
• Imfinzi · AstraZeneca
  Imfinzi works by blocking the PD-L1 protein, allowing the immune system to recognize and attack cancer cells.
• Alimta · Actavis
  Alimta works by inhibiting the enzyme dihydrofolate reductase, which is necessary for DNA synthesis and cell division.
• Photodyn · Hepatopancreatobiliary Surgery Institute of Gansu Province
  Photodyn works by being activated by light, which then kills cancer cells through a process called photodynamic therapy.
• Vinorelbin · National Cancer Institute, Slovakia
• Taxol · Pfizer
  Taxol works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division.
• Lorbrena · Pfizer
  Lorbrena works by blocking the activity of the ALK tyrosine kinase receptor, which is a protein that helps cancer cells grow.
• Navelbine · University of California, San Francisco
• Pf-06882961 · Pfizer
  Not specified
• Pembrolizuma · Memorial Sloan Kettering Cancer Center
• Taxotere · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Imfinzi · University Medical Center Groningen
• Alecensa · Hoffmann-La Roche
  Alecensa blocks the activity of the ALK protein, which is involved in the growth and spread of cancer cells.
• Docetaxol · Fudan University
• OFEV® · Boehringer Ingelheim
• Gemzar · Accord Hlthcare
  Gemzar works by mimicking a building block of DNA, tricking cancer cells into incorporating it into their DNA and then stopping the replication process.
• Iressa · Pfizer Inc.
  Iressa blocks the epidermal growth factor receptor (EGFR) signaling pathway, preventing cancer cell growth and proliferation.
• Taxol · Pfizer
• Lorbrena · Pfizer
  Lorbrena works by blocking the activity of the ALK tyrosine kinase receptor, which is a protein that helps cancer cells grow.
• Xalkori · Pfizer
  Xalkori works by blocking the hepatocyte growth factor receptor, a protein that helps cancer cells grow and spread.
• PF-07850327, ARV-471, vepdegestrant · Pfizer
• Tarceva · Osi Pharms
  Tarceva works by blocking the epidermal growth factor receptor, a protein that helps cancer cells grow.
• Xalkori · Pfizer
  Xalkori works by blocking the hepatocyte growth factor receptor, a protein that helps cancer cells grow and spread.
• Photofrin · Concordia Labs Inc
• Cyramza · Eli Lilly
  Cyramza blocks the VEGFR2 receptor, which is involved in cancer cell growth and spread.
• PF-06882961 (Cohort 3) · Pfizer
• Anti-OX40 Antibody PF-04518600 · Pfizer
• Navelbine · Pierre Fabre
  Navelbine works by binding to the Substance-K receptor, disrupting microtubule formation and inhibiting cell division.
• Opdivo · Bristol-Myers Squibb
  Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells.
• Taxotere · Sanofi
  Taxotere works by binding to microtubules, preventing them from disassembling and thereby blocking cell division.
• Gavreto · Rigel Pharms
  Pralsetinib inhibits RET kinase and its oncogenic fusions/mutations, blocking downstream signaling and reducing tumor growth.
• Taxol · Pfizer
• Lorviqua · Pfizer Inc.
  As provided in real world practice
• Pemetrexe · Rongjie Tao
• Abraxane · The First Affiliated Hospital with Nanjing Medical University
• vargatef · ARCAGY/ GINECO GROUP
• Tarceva · M.D. Anderson Cancer Center
• Taxol · M.D. Anderson Cancer Center
• Photofrin · Samsung Medical Center

Clinical guidelines

• FDA label — 1L
  Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC).
• FDA label — 2L|1L
  Docetaxel is indicated as a single agent for locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also indicated in combination with cisplatin for unresectable, locally advanced or metastatic untreated non-small cell lung cancer.
• FDA label — any
  XALKORI is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test.
• FDA label — 1L
  Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC).
• FDA label — neoadjuvant/adjuvant
  IMFINZI in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery.
• FDA label — maintenance
  IMFINZI as a single agent for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
• FDA label — maintenance
  IMFINZI as a single agent for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
• FDA label — any
  XALKORI is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test.
• FDA label — 1L|2L|3L+|maintenance
  Erlotinib is indicated for the treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test, receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.
• FDA label — any
  ZYKADIA is a kinase inhibitor indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• Non-small cell lung cancer patent landscape — cliff calendar, originator estates, attackable patents
• Non-small cell lung cancer treatment landscape brief
• Non-small cell lung cancer treatment updates RSS

Frequently asked questions about Non-small cell lung cancer

Related

• Treatment landscape: Non-small cell lung cancer patent cliff · Non-small cell lung cancer CI report
• Treatment: PF-07220060 + PF-07104091 combination dose escalation · Pfizer
• Treatment: PF-06939999 in combination with docetaxel · Pfizer
• Treatment: Alunbrig · Takeda
• Treatment: ICOTINIB · Zhejiang Beta Pharma Inc.
• Treatment: Gemcitabin · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing